Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer

J Clin Oncol. 2020 May 20;38(15):1746. doi: 10.1200/JCO.20.00149. Epub 2020 Mar 25.

Authors

Pirus Ghadjar¹, Dirk Böhmer¹, Stefan Höcht¹, Felix Sedlmayer¹, Thomas Wiegel¹

Affiliation

¹ Pirus Ghadjar, MD and Dirk Böhmer, MD, PhD, Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin, Germany; Stefan Höcht, MD, PhD, Xcare Praxis für Strahlentherapie Saarlouis, Xcare Gruppe, Saarlouis, Germany; Felix Sedlmayer, MD, Landeskrankenhaus, Universitätsklinikum der Paracelsus Medizinischen Privatuniversität, Salzburg, Austria; and Thomas Wiegel, MD, University of Ulm, Ulm Germany.

PMID: 32209006
DOI: 10.1200/JCO.20.00149

No abstract available

Publication types

Letter
Comment

MeSH terms

Androgen Antagonists*
Androgens
Humans
Male
Prostate-Specific Antigen
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / radiotherapy

Substances

Androgen Antagonists
Androgens
Prostate-Specific Antigen